OliX Pharmaceuticals seeks FDA nod for phase 2a trial of OLX10010
OliX Pharmaceuticals, a South Korean pharma company, has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) seeking its consent to begin a phase 2a clinical trial for OLX10010 in reducing the recurrence of hypertrophic scars after scar revision surgery. The developer of RNAi therapeutics intends to assess the […]
SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia
September 12, 2020 No Comment
SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for its FDA-approved seizures drug cenobamate in Asia. Cenobamate was approved by the US Food and Drug Administration as an anti-seizure medication (ASM) under the brand name XCOPRI for the treatment of partial-onset seizures in adults. (Read here […]
Continue reading …Celltrion begins phase 1 human trial of COVID-19 antiviral antibody candidate
July 19, 2020 No Comment
Celltrion Group, a South Korean pharma company, has launched a phase 1 human clinical trial of a potential antiviral antibody treatment for COVID-19 patients. The in-human study of the COVID-19 antiviral antibody comes in the wake of the positive results delivered by it in pre-clinical studies and the following approval of the investigational new drug […]
Continue reading …SK Biopharmaceuticals bags XCOPRI FDA approval for partial-onset seizures
November 23, 2019 No Comment
XCOPRI FDA approval : SK Biopharmaceuticals said that its US subsidiary SK Life Science has been granted approval from the US Food and Drug Administration (FDA) for its anti-epileptic drug XCOPRI (cenobamate tablets) for the treatment for partial-onset seizures in adults. According to the FDA, a seizure is normally a short episode of abnormal electrical activity […]
Continue reading …
Yuhan Pharmaceuticals has entered into a collaboration with Canadian biotechnology company Cyclica to use the latter’s artificial intelligence (AI) driven integrated drug discovery platform in two separate research and development (R&D) programs in oncology. The South Korean healthcare company said that it is looking to adopt innovative technologies to boost its drug development efforts. In […]
Continue reading …Samsung Bioepis, C-Bridge Capital collaborate to develop and commercialize biosimilars in China
February 11, 2019 No Comment
Samsung Bioepis, a South Korean biopharma company, has signed a licensing agreement with private equity firm C-Bridge Capital to develop and commercialize next-generation biosimilars in China. The agreement covers Samsung Bioepis’ various biosimilar candidates like SB11 and SB12, which reference LUCENTIS (ranibizumab) and SOLIRIS (eculizumab), respectively, and also SB3, a biosimilar candidate referencing HERCEPTIN 3 […]
Continue reading …LEO Pharma bags licensing rights for atopic dermatitis drug JW1601 from JWP
August 27, 2018 No Comment
LEO Pharma, a Danish pharma company, has bagged global exclusive rights for atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP) in a deal worth around KRW450 billion ($402 million). The global licensing agreement will not cover South Korea, the home country of JWP, where the Korean pharma company will keep its exclusive rights over the […]
Continue reading …
Business News Today
- USI Insurance Services acquires actuarial consulting firm Hildi
- Chr. Hansen to sell natural colors business to EQT for $800m
- Boxlight acquires AV solutions provider Sahara Presentation System
- SSGT II acquires two self storage facilities near Tampa, Florida
- Preferred Apartment Communities to sell student housing portfolio to TREP
- Corbion, Total to build €200m PLA bioplastics plant in France
- iPipeline acquires Impact Financial Systems
- Nautilus Solar Energy acquires 17MW solar portfolio from Pine Gate Renewables
- Palladium Equity Partners acquires majority stake in Trachte USA from MPE Partners
- The Hilb Group acquires life and health agency Ganim Benefits in Connecticut
